Calamos Advisors LLC Sells 1,759 Shares of Eli Lilly and Company $LLY

Key Points

• Calamos Advisors LLC trimmed its stake in Eli Lilly by 0.6%, selling 1,759 shares and retaining 272,554 shares worth about $292.9 million, making LLY its 11th-largest position.
• Eli Lilly beat Q1 estimates with $7.54 EPS and $19.29 billion in revenue (up 42.6% YoY) and set FY 2026 guidance of 33.50–35.00 EPS.
• The company is expanding via deals — agreeing to acquire Ajax Therapeutics for up to $2.3 billion and partnering with AI firm Profluent (reported up to $2.25 billion) — even as GLP‑1 competition rises and analysts remain broadly bullish with a consensus target near $1,216.52.

Calamos Advisors LLC lowered its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 0.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 272,554 shares of the company's stock after selling 1,759 shares during the period. Eli Lilly and Company comprises approximately 1.1% of Calamos Advisors LLC's holdings, making the stock its 11th largest position. Calamos Advisors LLC's holdings in Eli Lilly and Company were worth $292,908,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of LLY. Capital Research Global Investors boosted its holdings in Eli Lilly and Company by 20.9% in the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company's stock worth $19,141,787,000 after buying an additional 4,332,008 shares during the period. Amundi boosted its holdings in Eli Lilly and Company by 27.1% in the 3rd quarter. Amundi now owns 4,525,902 shares of the company's stock worth $3,823,977,000 after buying an additional 964,675 shares during the period. Victory Capital Management Inc. boosted its holdings in Eli Lilly and Company by 47.6% in the 3rd quarter. Victory Capital Management Inc. now owns 2,309,006 shares of the company's stock worth $1,761,772,000 after buying an additional 744,868 shares during the period. Danske Bank A S bought a new position in Eli Lilly and Company in the 3rd quarter worth $512,022,000. Finally, Capital International Investors boosted its holdings in Eli Lilly and Company by 6.1% in the 3rd quarter. Capital International Investors now owns 10,001,509 shares of the company's stock worth $7,628,447,000 after buying an additional 579,381 shares during the period. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 0.7%

Shares of NYSE:LLY opened at $874.14 on Wednesday. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The company has a 50-day moving average price of $952.17 and a 200 day moving average price of $986.25. The company has a market cap of $825.91 billion, a price-to-earnings ratio of 38.09, a PEG ratio of 1.03 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating analysts' consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. During the same quarter last year, the firm earned $5.32 EPS. The firm's revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities research analysts predict that Eli Lilly and Company will post 33.9 earnings per share for the current year.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Acquisition — Lilly agreed to buy Ajax Therapeutics for up to $2.3 billion, adding a Type II JAK2 inhibitor for myelofibrosis and expanding its hematology/oncology pipeline. Eli Lilly to acquire Ajax Therapeutics for up to $2.3 billion
• Positive Sentiment: AI drug‑discovery partnership — Lilly struck a deal with AI startup Profluent (reported as up to $2.25 billion), signaling investment in AI-enabled discovery that could accelerate new programs and cost efficiency. Emeryville AI Upstart Snags $2.25 Billion Gene Editing Deal With Eli Lilly
• Positive Sentiment: Analyst support — Multiple analysts and outlets have reiterated bullish views (e.g., Barclays Overweight with a $1,350 target), supporting the narrative that Lilly’s deal cadence and diversified pipeline justify higher valuation. Analysts Reiterate Bullish Outlook on Eli Lilly and Company (LLY) Following Kelonia Acquisition
• Neutral Sentiment: Sector tone — Health‑care stocks broadly edged higher midday, providing modest tailwinds for large-cap pharma names including LLY. Sector Update: Health Care Stocks Edge Higher Late Afternoon
• Neutral Sentiment: Near‑term earnings focus — Analysts are parsing Q1 guidance and launch metrics ahead of results; market reaction may hinge on GLP‑1 trends and margins. Countdown to Lilly (LLY) Q1 Earnings: Wall Street Forecasts for Key Metrics
• Negative Sentiment: GLP‑1 competitive pressure — Data and prescription tracking show Novo Nordisk’s oral Wegovy gaining share vs. Lilly’s oral competitor, raising concerns about Foundayo adoption and near‑term revenue growth. GLP-1 pill race heats up as Wegovy tablet holds strong against Lilly rival
• Negative Sentiment: New competitor data — A late‑stage obesity trial from Boehringer/Ingelheim showed meaningful weight loss, intensifying competition in the obesity space where Lilly has been a market leader. Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial
• Negative Sentiment: Short‑term pullback/volatility — Shares pulled back with the broader market ahead of earnings as investors weigh pricing pressure, rising costs and softer launch datapoints. Pharmaceutical Stock Pulling Back Before Earnings

Analyst Ratings Changes

Several research analysts have commented on LLY shares. Barclays started coverage on shares of Eli Lilly and Company in a report on Thursday, February 19th. They set an "overweight" rating and a $1,350.00 price objective for the company. Sanford C. Bernstein reissued an "outperform" rating on shares of Eli Lilly and Company in a report on Tuesday, March 10th. Weiss Ratings reissued a "buy (b)" rating on shares of Eli Lilly and Company in a report on Friday, March 27th. Royal Bank Of Canada started coverage on shares of Eli Lilly and Company in a report on Tuesday, February 24th. They set an "outperform" rating and a $1,250.00 price objective for the company. Finally, Jefferies Financial Group set a $1,300.00 price objective on shares of Eli Lilly and Company and gave the company a "buy" rating in a report on Friday, March 13th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $1,216.52.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.